IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
REGENERON-R15505-ONC-24144
Phase I/II
OPEN TO ACCRUAL
Phase 1/2 Study of REGN15505 (a PSMAx4-1BB Bispecific Antibody) Administered Alone or in Combination with Cemiplimab or REGN4336 (a PSMAxCD3 Bispecific Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma